Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

43 results about "Antipsychotic drug" patented technology

Antipsychotics are drugs that are used to treat symptoms of psychosis such as delusions (for example, hearing voices), hallucinations, paranoia, or confused thoughts. They are used in the treatment of schizophrenia, severe depression and severe anxiety. Antipsychotics are also useful at stabilizing episodes of mania in people with Bipolar Disorder.

Composition and Method for Treatment of Depression and Psychosis in Humans

Compositions and methods tor the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and / or antidepressant medications and also containing an NMPAR antagonist. The present invention is also directed to methods for the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and / or antipsychotic effective amounts.
Owner:GLYTECH

Hypodermic syringes with multiple needles and methods of calming psychiatric patients using such

InactiveUS20060079846A1Infusion syringesIntravenous devicesSedating AntihistaminesMentally ill
Hypodermic syringes with multiple needles are used to practice a method of calming psychiatric patients. In accordance with one embodiment of the invention generally used to calm violent adult patients, the syringe has a first barrel containing an antipsychotic, a second barrel containing a sedating antihistamine and a third barrel containing an antianxiety sedative. Each barrel also has a separate projecting needle and contains a piston. A common operator, preferably in the form of a plunger simultaneously pushes all of the pistons so that the patient receives three injections simultaneously. For children, a second embodiment of the syringe includes two barrels instead of three, each barrel containing a separate medication. In each embodiment the syringe is packaged in a manually openable plastic envelope with a safety cap over the needles.
Owner:WILLIAMS ALTON

Method for identifying antipsychotic drug candidates

The present invention provides a method for identifying a compound or a combination of compounds having a pharmacological behavior that qualifies it as a candidate for clinical development of a drug for treatment of a psychiatric disease or disorder, preferably schizophrenia. According to this method, a candidate drug is assessed for its ability to produce a biochemical profile, in either or both in vitro and in vivo test systems, which is similar to a unique reference biochemical profile obtained following treatments with drugs or drug combinations effective against both positive and negative symptoms of psychiatric diseases or disorders.
Owner:TECHNION RES & DEV FOUND LTD

Artemisinin Derivatives

ActiveUS20100093651A1BiocideNervous disorderParasitic infectious diseaseMedicine
This disclosure provides improved derivatives of artemisinin; pharamaceutical compositions containing these compounds; methods for preparing these compounds and compositions; methods of using these compounds and compositions for preventing, controlling or treating infectious diseases including but not limited to parasitic infectious diseases such as T. gondii infection, trypanosome parasite infection, plasmodia parasite infection, and cryptosporidium parasite infection; methods for preventing, controlling or treating toxoplasma infection; and methods for treating psychiatric disorders associated with toxoplasma infection including but not limited to schizophrenia using the disclosed compounds and compositions alone or in combination with one or more antipsychotic drugs.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

Methods of treating schizophrenia

The invention provides methods for the treatment of abnormal psychiatric states, particularly the negative symptoms of schizophrenia and extrapyramidal side effects (EPS) of antipsychotic drugs. The inventive methods relate to the administration of therapeutic cells (which produce dopamine or dopamine precursors) adhered to support matrices to subjects suffering from the negative symptoms of schizophrenia and / or EPS. The therapeutic cells may be coadministered with cells which protect the therapeutic cells from immune rejection and / or cells which produce neurotrophic factors which improve the viability of the therapeutic cells.
Owner:TITAN PHARMA

Intranasal delivery of antipsychotic drugs

InactiveUS20060039869A1Rapid systemic availabilityAvoidance of hepatic first metabolismBiocidePowder deliveryPsychosis drugNebulizer
An intranasal drug product is provided including an antipsychotic drug, such as haloperidol, in sprayable solution in an intranasal metered dose sprayer. Also provided is a method of administering an antipsychotic drug, such as haloperidol, to a patient, including the step of delivering an effective amount of the antipsychotic drug to a patient intranasally using an intranasal metered dose sprayer. A method of treating a psychotic episode also is provided, the method including the step of delivering an antipsychotic drug, such as haloperidol, intranasally in an amount effective to control the psychotic episode.
Owner:UNIV OF KENTUCKY RES FOUND

Treatment of sequelae of psychiatric disorders

In general, the invention provides methods and compositions for treating sequela of weight gain or pain insensitivity, e.g., in a subject suffering from a psychiatric disorder, such as schizophrenia. The combinations employed in the invention include a second generation antipsychotic agent and an opioid receptor antagonist.
Owner:INNOVORSO LLC +1

Multiple gene detection kit for guiding antipsychotic drugs and using method thereof

The invention discloses a multiple gene detection kit for guiding antipsychotic drugs and a using method thereof. The kit adopts multiple PCR combined with a fragment length / mass analysis method and synchronously and qualitatively detects 7 nucleotide polymorphism (SNP) locus on 6 genes including CYP2D6, MC4R, CYP1A2, CYP3A5, EPM2A, and SLC6A2 which are related to antipsychotic drug metabolism, transport and target action. The method comprises the detection steps of (1) collecting oral exfoliated cells and storing on a cell collection card or collecting blood samples and extracting nucleic acids; (2) performing multiple PCR amplification using the cell collection card or nucleic acid as described in step 1 as formwork; (3) according to PCR product fragment length / mass, simultaneously separating into 7 SNP loci, 3 human DNA internal reference genes and 1 PCR reaction internal reference PCR product; (4) analyzing results and interpreting. The kit has the advantages of fast performance, high sensitivity, good repeatability, strong specificity, high throughput and low cost.
Owner:NINGBO HEALTH GENE TECHNOLOGIES CO LTD

Benzoisothiazole compounds and use in preparation of antipsychotic drugs

Disclosed are benzoisothiazole compounds and a use in the preparation of anti-schizophrenia drugs. The benzoisothiazole compounds of the present invention not only have strong affinity for dopamine D3 receptor, 5-HT1A receptor and 5-HT2A receptor, but also can observably improve the symptoms of schizophrenia relevant to apomorphine model and MK-801 model mice, with oral absorption being good, safety being high and side-effect being less, and having developmental value as new anti-neurotic disease drugs. The present invention is the compounds having a structure of general formula (I), or geometric isomers, free alkalies, salts, hydrates or solvates thereof.
Owner:SHANGHAI INST OF PHARMA IND

Use and preparation method of pinosylvi

InactiveCN109758438AStrong neuroinhibitionNervous disorderOrganic chemistryMedicineBiological activation
The invention provides use and preparation method of pinosylvin. The pinosylvin is used for preparing a medicine for inhibiting nerve activity, and is also used for preparing an antipsychotic drug. Itis found through the study of the pinosylvi that the pinosylvi has a strong function of blocking the activation of a nerve signal transduction system, and further experiments prove that the pinosylvicrystal can be specifically combined with a neuron and a strong neural inhibition effect occurs.
Owner:NANTONG UNIVERSITY

Antipsychotic drug related metabolism syndrome susceptible gene and application thereof

The invention provides an antipsychotic drug related metabolism syndrome susceptible gene and an application thereof, and concretely relates to a use of a separate single-nucleotide polymorphism (SNP) site-containing polynucleotide or a detection reagent thereof in the preparation of kits for detecting antipsychotic drug related metabolism syndrome susceptibility. The SNP site in the polynucleotide corresponds to human chromosome 17p11.2 region (chr17:17708129(GRCh37 / hg19)), rs11654081, C to T. The susceptibility of individuals to antipsychotic drug related metabolism syndrome can be judged in an adjuvant manner through detecting the gene and SNP, and a new approach is provided for diagnosis and corresponding treatment of the syndrome; and additionally, the discovery of the gene and the SNP also provides a new drug target for developing drugs for treating the related metabolism syndrome, and the gene and the SNP can be used as syndrome patient regression and prognosis molecule markers.
Owner:SHANGHAI MENTAL HEALTH CENT (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENT)

Method for preparing benzisoxazole antipsychotic drug risperidone

The invention relates to a method for preparing a benzisoxazole antipsychotic drug risperidone and belongs to the technical field of preparation of risperidone. The method for preparing a benzisoxazole antipsychotic drug risperidone comprises the following step of carrying out cyclization reaction on (z)-[3-[4-[(2,4-difluorophenyl)methyloximido]piperidinyl]-1-ethyl]-2-methyl-6,7,8,9-4H-pyridino[1,2-a]pyrimidin-4-one serving as a starting material in a mixed solvent of dichloromethane and concentrated alkali water to prepare the target product risperidone. The method is simple in operation and low in requirements on the device, the prepared product is high in purity and is suitable for industrial production.
Owner:REYOUNG PHARMA

Double-antibody sandwich chemiluminescence immune assay method

InactiveCN108387747AThe phenomenon of serum reduction was foundBiological testingNeuropsychiatric diseaseTherapeutic effect
The invention belongs to biomedical field, and relates to a double-antibody sandwich chemiluminescence immune assay method. The method comprises the following steps: adopting an anti-RPTN N-terminal mouse monoclonal antibody as a capturing antibody coated on an elisa plate, adding serum to be measured or RPTN standard after washing, and adding an RPTN C-terminal rabbit polyclonal antibody as a detection antibody after washing; adding goat anti-rabbit IgG-HRP after washing, and adding a luminal reaction solution after washing; and measuring chemiluminiscence (RLU) on a chemiluminiscence immuneanalyzer after washing, wherein the intensity of RLU represents the content of RPTN. The method firstly discovers the phenomenon that the RPTN inside the serum of a schizophrenic patient is reduced, an RPTN chemiluminescence immune method is further developed and the normal range of the RPTN inside the serum is detected and determined, and a novel method is provided for diagnosis and therapeutic effect evaluation of schizophrenia; and a novel tool is provided for the research of other neuropsychiatric diseases and the research and development of antipsychotic drugs.
Owner:SHAANXI NORMAL UNIV

Anti-Psychotic Composition and Treatment Methods

ActiveUS20200197473A1Improve negative symptomsOrganic active ingredientsNervous disorderSchizo-affective typeAntipsychotic drug therapy
Provided herein are methods of treatment of psychiatric disorders requiring treatment with an antipsychotic drug, such as schizophrenia or schizoaffective disorder, comprising administration of both the antipsychotic drug and a W. somnifera plant part, extract, chemical constituent(s) thereof, or a derivative thereof to treat symptoms of the psychiatric disorder. Treatment is typically continued for at least four weeks. A combination dosage form comprising both the antipsychotic drug and the W. somnifera plant part, extract, chemical constituent(s) thereof, or a derivative thereof in amounts effective to treat the psychiatric disorder.
Owner:UNIVERSITY OF PITTSBURGH

Methods and compositions for treating schizophrenia and schizoaffective disorders

ActiveUS11219659B2Organic active ingredientsNervous disorderSchizo-affective typeAntipsychotic drug therapy
Provided herein are methods of treatment of psychiatric disorders requiring treatment with an antipsychotic drug, such as schizophrenia or schizoaffective disorder, comprising administration of both the antipsychotic drug and a W. somnifera plant part, extract, chemical constituent(s) thereof, or a derivative thereof to treat symptoms of the psychiatric disorder. Treatment is typically continued for at least four weeks. A combination dosage form comprising both the antipsychotic drug and the W. somnifera plant part, extract, chemical constituent(s) thereof, or a derivative thereof in amounts effective to treat the psychiatric disorder.
Owner:UNIVERSITY OF PITTSBURGH

Sustained-release pharmaceutical compositions comprising an antipsychotic drug and uses thereof

The present invention relates to a pharmaceutical composition comprising at least one liposome and an antipsychotic drug with a high drug to lipid ratio and encapsulation efficiency. The pharmaceutical composition improves the pharmacokinetic profile and sustains the release of the antipsychotic drug. Also provided is the method for treating schizophrenia or bipolar disorder using the pharmaceutical composition disclosed herein.
Owner:TAIWAN LIPOSOME CO LTD +1

Intelligent medicine taking prompting system and method

PendingCN113662858AActive medication effectActively pick up the intention of takingPharmaceutical containersMedical packagingPharmaceutical drugPsychiatry
The invention provides an intelligent medicine taking prompting system which comprises a medicine composition for treating bipolar affective disorder and a medicine composition taking prompting system for cooperating with the attack cycle of the bipolar affective disorder, and the medicine composition comprises one or more of three medicine taking windows. The medicine taking windows comprise a mood stabilizer for mania or lightness, an antidepressant or antipsychotic agent for depressive phase or a sustained release agent for intermittent phase. The outer surface of the mood stabilizer is partially or completely provided with an edible outer coating containing one or more of color systems P, PB, B, BG or G so as to resist the conflict psychology of medicine taking during manic period medicine taking. The antidepressant or antipsychotic agent is used for resisting the negative heart state of the medicine, and an outer coating formed by one or more colors of GY, Y, TR, R or RP is arranged on the outer surface of the agent.
Owner:XUANWU HOSPITAL OF CAPITAL UNIV OF MEDICAL SCI

Pharmaceutical composition for treatment of cancer using phenothiazine

The present invention relates to use of antipsychotic phenothiazine derivative for treatment of cancer. The invention also provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating a cancer, and / or preventing or delaying cancer recurrence based on trifluoperazine. The invention further provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating cancer based on thioridazine and its enantiomers. Additionally, the invention provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating KRAS mutant NSCLC comprising thioridazine.
Owner:NATIONAL YANG MING UNIVERSITY

Preparation method of antipsychotic drug olanzapine

The invention relates to a preparation method of an antipsychotic drug olanzapine. The method comprises three steps: first, using sulfur, propionaldehyde and malononitrile as raw materials, triethylamine as a catalyst to carry out ringclosure to obtain 5-methyl-2-amino-3-cyanothiophene; second, the 5-methyl-2-amino-3-cyanothiophene and o-fluoronitrobenzene generating 5-methyl-2-(2- nitrophenylamino)-3-cyanothiophene under effects of sodium hydride; third, the 5-methyl-2-(2- nitrophenylamino)-3-cyanothiophene reacting with hydrazine hydrate and N-methyl piperazine to carry out ringclosure reaction under existence of ferric trichloride / active carbon catalyst; so as to generate objective compound olanzapine through a one-pot method. The invention has the advantages of cheap and easily available raw materials, few steps, and simple process. A one-pot reaction is carried out in the third step, so that intermediate state compounds during the reaction process do not need to be separated or removed and can converse into the objective compound, and the high-purity olanzapine can be obtained with high yield. The whole process is suitable for industrial mass production with high product yield, low costs and convenient post-treatment.
Owner:宁波人健化学制药有限公司

Preparation method of important intermediate of amisulpride

4-amino-5-thiophenol-2-methoxymethyl benzoate is an important intermediate of the antipsychotic drug amisulpride. The invention relates to a preparation method of 4-amino-5-thiophenol-2-methoxymethylbenzoate. The method is mild in reaction conditions, easy to operate and simple in purification process.
Owner:BEIJING VENTUREPHARM BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products